Pharmaceutical tablet
Latest Hanmi Pharm. Co., Ltd. Patents:
- Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
- Methods of treating neutorpenia using G-CSF protein complex
- Sulfonamide derivative with fused pyrimidine skeleton, having epidermal growth factor receptor mutation inhibitory effect
- LIVER-TARGETED SUBSTANCE AND USE THEREOF
- Lyophilized formulation of long-acting human growth hormone immunoglobulin conjugate
Description
The portions shown in broken lines do not form part of the claimed design and are hereby disclaimed.
Claims
The ornamental design for a pharmaceutical tablet, as shown and described.
Referenced Cited
U.S. Patent Documents
1243501 | October 1917 | Fraser |
4503031 | March 5, 1985 | Glassman |
D303160 | August 29, 1989 | Tovey |
5395625 | March 7, 1995 | Tang |
D397507 | August 25, 1998 | Bern |
D447835 | September 11, 2001 | Whitaker et al. |
D516714 | March 7, 2006 | McAllister et al. |
D553414 | October 23, 2007 | Boutin |
D556319 | November 27, 2007 | Chen et al. |
D557797 | December 18, 2007 | Stawski et al. |
Patent History
Patent number: D700315
Type: Grant
Filed: Jan 23, 2013
Date of Patent: Feb 25, 2014
Assignee: Hanmi Pharm. Co., Ltd. (Gyeonggi-Do)
Inventors: Dong Ho Kim (Gyeonggi-do), Ki Boong Lee (Gyeonggi-do)
Primary Examiner: Ian Simmons
Assistant Examiner: Charles Hanson
Application Number: 29/443,875
Type: Grant
Filed: Jan 23, 2013
Date of Patent: Feb 25, 2014
Assignee: Hanmi Pharm. Co., Ltd. (Gyeonggi-Do)
Inventors: Dong Ho Kim (Gyeonggi-do), Ki Boong Lee (Gyeonggi-do)
Primary Examiner: Ian Simmons
Assistant Examiner: Charles Hanson
Application Number: 29/443,875
Classifications
Current U.S. Class:
Scored For Dosage Control (D24/103)